Nucleic Acid Vaccine Segmentation for Cold Chain Elimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid vaccines require cold storage and are not stable at refrigerated or ambient temperatures, limiting their accessibility to regions without reliable electricity or freezing infrastructure.
Innovation Solution
The vaccine components, particularly nucleic acids and transfection reagents, are stored separately and stabilized, allowing for a two-step preparation process where they are combined just before use to form a stable vaccine complex, which can be administered at various temperatures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If nucleic acid vaccines are formulated with transfection reagents for efficient cellular delivery, then transfection efficiency is improved, but the vaccine requires cold storage and loses stability at refrigerated or ambient temperatures
Solution Approach 1:
The vaccine is divided into two separate components: a nucleic acid component and a transfection reagent component. Each component can be stored independently at stable temperatures. When administered, they are combined in situ to form the active vaccine complex, achieving both high transfection efficiency and temperature stability during storage and transport.
2Reliability
If nucleic acid vaccines are stored at cold temperatures to maintain stability, then vaccine efficacy is preserved, but accessibility to remote areas without reliable electricity or freezing infrastructure is limited
Solution Approach 1:
By segmenting the vaccine into stable separate components that can be stored at ambient temperatures, the invention eliminates the need for cold chain infrastructure. The components maintain their stability and can be transported to and stored in remote areas without reliable electricity, then combined when needed to deliver effective vaccination.
3Ease of operation
If nucleic acids are delivered with transfection reagents in a pre-formed complex, then cellular uptake is enhanced, but the formulation becomes sensitive to temperature fluctuations and requires freezing
Solution Approach 1:
The pre-formed complex is avoided by delivering the nucleic acid and transfection reagent as separate stable components. Upon administration, they self-assemble or are mixed to form the complex at the site of injection, achieving enhanced cellular uptake while allowing both components to be stored separately at stable, non-freezing temperatures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the vaccine to remain stable at freezer, refrigeration, and room temperatures, extending its shelf life and allowing for administration without the need for cold chain storage, thereby increasing accessibility to remote areas.
Implementation Method 1
A nucleic acid carrier envelope is usually required to shield the negative charges and allow the nucleic acid to travel through the cell wall more easily
Implementation Method 2
Synthetic nucleic acid delivery agents include liposomes and polymers that carry cationic charges. These reagents aid formation of the nucleic acid into nanoparticle complexes
Implementation Method 3
Sucrose, a sugar is also used in the Pfizer vaccine. The sugar helps the vaccine molecules maintain their shape during freezing
Implementation Method 4
Naked mRNA, at least to a small degree, can cross the cell lipid bilayer to reach cytoplasm
Data Source
AI summary
Nucleic acid and the nanocomplex reagents are combined to create a vaccine. They are stable and stored separately without degradation. The vaccine components can be stored at a wide range of temperatures. The nucleic acids are stabilized and stored in a column, syringe, vial or chamber as a solid, lyophilized or precipitated. They may be stored on a solid phase surface through electrostatic forces, non-polar interactions, hydrogen bonding, polar interactions or any other mechanism. The solid surface may be media in a column which may be contained in a syringe. Nucleic acid vaccines are prepared by a two-step process. The nucleic acid component is first stabilized and then mixed with nanocomplex reagents, particle forming reagents or other reagents.